Gibberellins: Obtaining the Invention Patent of "A Kind of Taxane Derivative and its Preparation Method and Application"

Gibell announced that they recently received an invention patent certificate issued by the National Intellectual Property Office. The patent is titled "A Derivative of Paclitaxel and Its Preparation Method, Application," with the patent number ZL202311469030.2. The application date was November 7, 2023, and the authorization announcement date was December 16, 2025. The patent holder is the company, and the patent term is 20 years. This invention can be used for impurity detection of paclitaxel anticancer compounds, facilitating quality control. Obtaining this patent will not have a significant impact on current operations, but it will help improve the intellectual property protection system and enhance competitiveness.